Last Updated on March 10, 2026 by The Health Master
NPPA
Download NPPA notification No. S.O. 1085(E) dt 27-02-2026, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 20 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 1085 (E) dt 27-02-2026 based on the decision of 143rd Authority meeting dated 27-02-2026.
The notification states as follows:
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
A table is given below the article
Note:
(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules, including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.
NPPA fixed Ceiling price of 6 scheduled formulations: November 2025
Table
| Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Atorvastatin and Clopidogrel Capsules | Each hard gelatin capsule contains: Atorvastatin Calcium IP Equivalent to Atorvastatin 40 mg (as pellets) Clopidogrel Bisulphate IP Equivalent to Clopidogrel 75 mg (as pellets) | 1 Capsule | M/s Macleods Pharmaceuticals Ltd. | 30.09 |
| 2 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each Hard Gelatin Capsule Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 10 mg (As Film Coated Atorvastatin Tablets IP) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel Tablets IP) Aspirin IP 75mg (As Aspirin Gastro- Resistant Tablets IP) | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd. | 6.19 |
| 3 | Atorvastatin, Clopidogrel and Aspirin Capsules | Each Hard Gelatin Capsule Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 20 mg (As Film Coated Atorvastatin Tablets IP) Clopidogrel Bisulphate IP Eq. to Clopidogrel 75 mg (As Film Coated Clopidogrel Tablets IP) Aspirin IP 75mg (As Aspirin Gastro- Resistant Tablets IP) | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd. | 8.80 |
| 4 | Bilastine & Montelukast Oral Suspension | Each 5 ml Suspension Contains: Bilastine IP 10 mg Montelukast Sodium IP eq. to Montelukast 4 mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Hetero Healthcare Ltd. | 1.75 |
| 5 | Bisoprolol Fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 2.5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Alkem Wellness Ltd. | 10.73 |
| 6 | Bisoprolol Fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumarate IP 5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Alkem Wellness Ltd. | 12.55 |
| 7 | Cetirizine Ophthalmic Solution | Each ml contains: Cetirizine Hydrochloride IP Eq. to Cetirizine 0.24% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative) | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Micro Labs Ltd. | 14.42 |
| 8 | Cetirizine Ophthalmic Solution | Each ml contains: Cetirizine Hydrochloride IP Eq. to Cetirizine 0.24% w/v Benzalkonium Chloride Solution IP 0.02% v/v (As preservative) | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Sun Pharma Laboratories Ltd. | 14.42 |
| 9 | Cilnidipine and Telmisartan Tablets | Each film coated tablet contains: Cilnidipine IP 10 mg Telmisartan IP 40 mg | 1 Tablet | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 8.57 |
| 10 | Dehydroepiandrosterone (DHEA) (Micronized) and Folic Acid Hard Gelatin Capsules | Each Hard Gelatin Capsule Contains: Dehydroepiandrosterone 25 mg (Micronized) Folic Acid IP 1.5 mg | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Mankind Pharma Ltd. | 12.42 |
| 11 | Empagliflozin, Sitagliptin & Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 10 mg Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Kollectcare Pvt. Ltd. | 14.22 |
| 12 | Empagliflozin, Sitagliptin & Metformin Hydrochloride Extended Release Tablets | Each film coated bilayer tablet contains: Empagliflozin 25 mg Sitagliptin Phosphate Monohydrate IP Equivalent to Sitagliptin 100 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Kollectcare Pvt. Ltd. | 16.36 |
| 13 | Ivermectin & Albendazole Tablets | Each uncoated chewable tablet contains: Ivermectin IP 6 mg Albendazole IP 400 mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd. | 28.34 |
| 14 | Levofloxacin Eye Drops | Composition: Levofloxacin Hemihydrate IP Eq. to Levofloxacin 0.5% w/v Benzalkonium Chloride 0.005% w/v (as preservative) | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.60 |
| 15 | Mecobalamin, Alpha Lipoic Acid, Vitamin D3, Pyridoxine Hydrochloride & Folic Acid Tablets | Each film coated tablet contains: Mecobalamin IP 1500 mcg Alpha Lipoic Acid IP 100 mg Vitamin D3 IP 1000 IU Pyridoxine Hydrochloride IP 3mg Folic Acid IP 1.5 mg | 1 Tablet | M/s JK Print Packs (Pharma Division) / M/s Mankind Prime Labs Pvt. Ltd. | 16.62 |
| 16 | Metoprolol Succinate ER, Cilnidipine & Telmisartan tablets | Each Film Coated Tablet Contains: Metoprolol Succinate IP 47.5 mg Eq. to Metoprolol Tartrate (As Extended Release) 50 mg Cilnidipine IP 10 mg Telmisartan IP 40 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Ipca Laboratories Ltd. | 14.35 |
| 17 | Metoprolol Succinate ER, Cilnidipine & Telmisartan tablets | Each Film Coated Tablet Contains: Metoprolol Succinate IP 23.75 mg Eq. to Metoprolol Tartrate 25 mg (As Extended Release) Cilnidipine IP 10 mg Telmisartan IP 40 mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Ipca Laboratories Ltd. | 11.45 |
| 18 | Rosuvastatin and Clopidogrel Tablets | Each film coated tablet contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg | 1 Tablet | M/s Sun Pharma Laboratories Ltd. | 16.32 |
| 19 | Tacrolimus Ointment | Composition: Tacrolimus IP 0.1%w/w | 1 gm | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 33.33 |
| 20 | Telmisartan & Cilnidipine Tablets | Each film coated tablet contains: Telmisartan IP 40 mg Cilnidipine IP 10 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 10.00 |
